In December 2025, Palvella requested a Preliminary Breakthrough Therapy Designation Advice meeting with the FDA which is anticipated for the first quarter of 2026. The Company plans to commence a ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects total U.S. net product sales for the fourth quarter of 2025 to be ...

Wilson Creek Operational Update Highwood Asset Management Ltd., is pleased to announce an operational update regarding its Wilson Creek operations. As previously announced, Highwood drilled 2 gross ...

Broadstone Net Lease, Inc. (NYSE: BNL) ("Broadstone," "BNL," the "Company," "we," "our," or "us"), today announced that it will re ...

Progyny’s presentation at the JP Morgan Healthcare Conference begins at 7:30 a.m. Pacific Time / 10:30 a.m. Eastern Time on Tuesday, January 13, 2026. Mr. Anevski will be joined by Mark Livingston, ...

Preliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-yearIntroduced 2026 revenue ...

We stay the course even while the path may shift. We are attentive, do not judge, present and create as we always have. After ...